Avita Medical Ltd (RCEL)

[Billr05]

Avita CMS Application Seen as Significant Catalyst: Bell Potter
By Tim Smith

(Bloomberg) -- Avita has filed a pass through payment application with the U.S. Centers for Medicare & Medicaid Services which has the scope to be a “significant catalyst” for the company, analyst John Hester writes in note.
If application is successful it would lead to reimbursement being paid separately for treatment of outpatient burns in both hospitals and surgical centers; Decision expected in early 2021
Clinical trials are continuing with first patient for the vitiligo study expected to be confirmed in Sept.
See enrollments of trauma and pediatric burns studies to restart before Christmas
Maintain buy; PT trimmed to A$15 from A$16
NOTE: Aug. 26: Avita Says July Unaudited Sales for RECELL System $1.83M
RCEL US Equity
Graphic Dashboard»
Related ticker:
RCEL US (Avita Therapeutics Inc)
To contact the reporter on this story:
Tim Smith in Sydney at [e-mail]